ZYXI
Zynex, Inc. [ZYXI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ZYXI Stock Summary
Top 10 Correlated ETFs
ZYXI
Top 10 Correlated Stocks
ZYXI
In the News
Zynex to Present at the Cantor Global Healthcare Conference
ENGLEWOOD, Colo. , Sept. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming Cantor Global Healthcare Conference, which is being held September 26 th-28th, 2023.
Zynex to Present at the H.C. Wainwright Global Investment Conference
ENGLEWOOD, Colo., Sept. 5, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming H.C.
Zynex, Inc. (ZYXI) Q2 2023 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q2 2023 Earnings Conference Call July 27, 2023 4:15 PM ET Company Participants Quinn Callanan - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Daniel Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day ladies and gentlemen, and welcome to the Zynex Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.08 per share a year ago.
Zynex, Inc. Sets Second Quarter 2023 Earnings Call
ENGLEWOOD, Colo. , July 20, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023.
Zynex: Strong Growth And Profitability Amid Financial Concerns
Zynex, a medical device manufacturer, has reported a 36% year-over-year increase in revenue in Q1 2023, reaching $42.2 million, with a 14% increase in net income. Despite short-term underperformance, the company shows strong profitability and growth potential, with a gross profit margin of nearly 80% and a substantial return on equity of 24.58%. Zynex's robust growth strategy and commitment to operational efficiency suggest a promising outlook, despite concerns related to its financial stability and stock performance.
Why Shares of Zynex Are Up Wednesday
Zynek makes electrotherapy devices to control pain. The company grew revenue and net income in the first quarter.
7 Stocks With 1,000% Upside Potential
While market advocates will wince at accusations that investing is nothing more than legalized gambling, for these stocks with massive upside potential, I for one will have to concede that only speculators should read ahead. Though these enterprises may have yield lifechanging returns, they can quickly leave you in the poor house.
Zynex, Inc. (ZYXI) Q1 2023 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q1 2023 Earnings Conference Call April 27, 2023 4:15 PM ET Company Participants Louisa Smith - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Daniel Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Adam Maeder - Piper Sandler Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter 2023 Earnings Conference Call.
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.03 per share a year ago.
ZYXI Financial details
ZYXI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.89 | 1.27 | 2.15 | 3.4 | 4.11 | |
| Net income per share | 0.27 | 0.27 | 0.24 | 0.45 | 0.44 | |
| Operating cash flow per share | 0.26 | 0.18 | 0.02 | 0.18 | 0.36 | |
| Free cash flow per share | 0.23 | 0.17 | 0 | 0.17 | 0.35 | |
| Cash per share | 0.28 | 0.39 | 1.05 | 1.11 | 0.52 | |
| Book value per share | 0.26 | 0.55 | 1.53 | 1.93 | 1.73 | |
| Tangible book value per share | 0.26 | 0.55 | 1.53 | 1.14 | 0.96 | |
| Share holders equity per share | 0.26 | 0.55 | 1.53 | 1.93 | 1.73 | |
| Interest debt per share | 0 | 0.13 | 0.2 | 0.92 | 0.71 | |
| Market cap | 94.54M | 255.29M | 455.88M | 347.29M | 535.08M | |
| Enterprise value | 84.41M | 245.94M | 424.04M | 339.77M | 541.89M | |
| P/E ratio | 9.9 | 26.9 | 50.24 | 20.31 | 31.39 | |
| Price to sales ratio | 2.96 | 5.61 | 5.69 | 2.67 | 3.38 | |
| POCF ratio | 10.05 | 40.5 | 557.31 | 49.98 | 38.93 | |
| PFCF ratio | 11.36 | 41.56 | -2.73K | 54.78 | 40.15 | |
| P/B Ratio | 10.07 | 12.93 | 8.02 | 4.7 | 8.06 | |
| PTB ratio | 10.07 | 12.93 | 8.02 | 4.7 | 8.06 | |
| EV to sales | 2.64 | 5.41 | 5.29 | 2.61 | 3.43 | |
| Enterprise value over EBITDA | 8.14 | 22.22 | 36.11 | 15.19 | 23.62 | |
| EV to operating cash flow | 8.97 | 39.02 | 518.38 | 48.89 | 39.42 | |
| EV to free cash flow | 10.14 | 40.04 | -2.54K | 53.59 | 40.66 | |
| Earnings yield | 0.1 | 0.04 | 0.02 | 0.05 | 0.03 | |
| Free cash flow yield | 0.09 | 0.02 | 0 | 0.02 | 0.02 | |
| Debt to equity | 0 | 0.24 | 0.13 | 0.47 | 0.41 | |
| Debt to assets | 0 | 0.17 | 0.1 | 0.26 | 0.23 | |
| Net debt to EBITDA | -0.98 | -0.85 | -2.71 | -0.34 | 0.3 | |
| Current ratio | 2.25 | 4.34 | 6.23 | 3.62 | 3.3 | |
| Interest coverage | 67.34 | 2.21K | 539.42 | 235.43 | 52.13 | |
| Income quality | 0.98 | 0.66 | 0.09 | 0.41 | 0.81 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0.01 | |
| Payout ratio | 0 | 0.24 | 0 | 0 | 0.21 | |
| Sales general and administrative to revenue | 0 | 0.25 | 0.23 | 0.2 | 0.23 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.23 | 0.25 | |
| Capex to operating cash flow | -0.12 | -0.03 | -1.2 | -0.09 | -0.03 | |
| Capex to revenue | -0.03 | 0 | -0.01 | 0 | 0 | |
| Capex to depreciation | -2.42 | -0.21 | -0.63 | -0.27 | -0.13 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Graham number | 1.26 | 1.82 | 2.89 | 4.4 | 4.15 | |
| ROIC | 1.03 | 0.3 | 0.13 | 0.13 | 0.16 | |
| Return on tangible assets | 0.59 | 0.34 | 0.13 | 0.17 | 0.2 | |
| Graham Net | 0.16 | 0.31 | 1.03 | 0.26 | 0.08 | |
| Working capital | 7.97M | 17.37M | 52.91M | 59.82M | 48.47M | |
| Tangible asset value | 9.3M | 19.65M | 56.86M | 43.55M | 36.89M | |
| Net current asset value | 7.44M | 13.94M | 47.7M | 23.34M | 19.45M | |
| Invested capital | 0 | 0.24 | 0.13 | 0.47 | 0.41 | |
| Average receivables | 2.49M | 4.31M | 9.84M | 21.23M | 31.85M | |
| Average payables | 1.9M | 1.84M | 3.43M | 4.73M | 5.17M | |
| Average inventory | 630K | 1.61M | 5.51M | 9.7M | 12.12M | |
| Days sales outstanding | 31.92 | 46.82 | 63.04 | 80.2 | 80.91 | |
| Days payables outstanding | 93.82 | 88.33 | 98.85 | 63.31 | 63.88 | |
| Days of inventory on hand | 50.6 | 98.48 | 180.96 | 143.7 | 153.78 | |
| Receivables turnover | 11.44 | 7.8 | 5.79 | 4.55 | 4.51 | |
| Payables turnover | 3.89 | 4.13 | 3.69 | 5.77 | 5.71 | |
| Inventory turnover | 7.21 | 3.71 | 2.02 | 2.54 | 2.37 | |
| ROE | 1.02 | 0.48 | 0.16 | 0.23 | 0.26 | |
| Capex per share | -0.03 | 0 | -0.03 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.95 | 1.09 | 1.31 | 1.15 | 1.23 | |
| Net income per share | 0.09 | 0.13 | 0.2 | 0.04 | 0.09 | |
| Operating cash flow per share | 0 | 0.19 | 0.13 | 0.05 | 0.02 | |
| Free cash flow per share | -0.01 | 0.19 | 0.13 | 0.05 | 0.01 | |
| Cash per share | 0.69 | 0.62 | 0.54 | 0.46 | 1.61 | |
| Book value per share | 1.78 | 1.71 | 1.78 | 1.76 | 1.71 | |
| Tangible book value per share | 1.01 | 0.93 | 0.99 | 0.96 | 0.91 | |
| Share holders equity per share | 1.78 | 1.71 | 1.78 | 1.76 | 1.71 | |
| Interest debt per share | 0.8 | 0.77 | 0.73 | 0.67 | 1.97 | |
| Market cap | 310.03M | 345.08M | 517.95M | 440.33M | 349.41M | |
| Enterprise value | 314.14M | 350.73M | 524.77M | 447.91M | 362.01M | |
| P/E ratio | 23.16 | 17.7 | 17.38 | 70.16 | 26.04 | |
| Price to sales ratio | 8.43 | 8.31 | 10.61 | 10.44 | 7.77 | |
| POCF ratio | -1.76K | 46.56 | 108.88 | 227.68 | 471.54 | |
| PFCF ratio | -981.11 | 47.33 | 110.89 | 251.62 | 658.03 | |
| P/B Ratio | 4.49 | 5.29 | 7.81 | 6.83 | 5.61 | |
| PTB ratio | 4.49 | 5.29 | 7.81 | 6.83 | 5.61 | |
| EV to sales | 8.55 | 8.45 | 10.75 | 10.62 | 8.05 | |
| Enterprise value over EBITDA | 62.57 | 47.67 | 51.91 | 177.18 | 95.27 | |
| EV to operating cash flow | -1.78K | 47.32 | 110.31 | 231.6 | 488.55 | |
| EV to free cash flow | -994.13 | 48.1 | 112.35 | 255.95 | 681.76 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0.02 | 0.01 | 0 | 0 | |
| Debt to equity | 0.45 | 0.45 | 0.41 | 0.38 | 1.15 | |
| Debt to assets | 0.26 | 0.25 | 0.23 | 0.22 | 0.47 | |
| Net debt to EBITDA | 0.82 | 0.77 | 0.67 | 3 | 3.32 | |
| Current ratio | 3.75 | 3.41 | 3.3 | 3.09 | 7.63 | |
| Interest coverage | 37.95 | 61.87 | 106.42 | 20.05 | 8.56 | |
| Income quality | -0.05 | 1.52 | 0.64 | 1.23 | 0.22 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 1.08 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.24 | 0.23 | 0.21 | 0.27 | 0.25 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.25 | 0.26 | 0.25 | 0.26 | 0.19 | |
| Capex to operating cash flow | 0.8 | -0.02 | -0.02 | -0.1 | -0.28 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.18 | -0.15 | -0.1 | -0.22 | -0.19 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 1.86 | 2.22 | 2.83 | 1.3 | 1.88 | |
| ROIC | 0.03 | 0.05 | 0.07 | 0.02 | 0.02 | |
| Return on tangible assets | 0.04 | 0.06 | 0.09 | 0.02 | 0.03 | |
| Graham Net | 0.11 | 0.05 | 0.08 | 0.04 | 0.01 | |
| Working capital | 51.81M | 47.61M | 48.47M | 44.11M | 93.47M | |
| Tangible asset value | 39.08M | 35.49M | 36.89M | 35.24M | 33.25M | |
| Net current asset value | 20.06M | 17.13M | 19.45M | 18.6M | 17.26M | |
| Invested capital | 0.45 | 0.45 | 0.41 | 0.38 | 1.15 | |
| Average receivables | 27.83M | 28.09M | 31.71M | 33.56M | 32.51M | |
| Average payables | 5.89M | 5.19M | 5.37M | 5.63M | 5.79M | |
| Average inventory | 14.03M | 14.47M | 13.93M | 13.83M | 14.25M | |
| Days sales outstanding | 68.12 | 61.45 | 64.66 | 68.42 | 65.98 | |
| Days payables outstanding | 64.51 | 55.12 | 53.7 | 54.86 | 57.56 | |
| Days of inventory on hand | 179.53 | 154.09 | 129.27 | 137.72 | 139.05 | |
| Receivables turnover | 1.32 | 1.46 | 1.39 | 1.32 | 1.36 | |
| Payables turnover | 1.4 | 1.63 | 1.68 | 1.64 | 1.56 | |
| Inventory turnover | 0.5 | 0.58 | 0.7 | 0.65 | 0.65 | |
| ROE | 0.05 | 0.07 | 0.11 | 0.02 | 0.05 | |
| Capex per share | 0 | 0 | 0 | -0.01 | -0.01 |
ZYXI Frequently Asked Questions
What is Zynex, Inc. stock symbol ?
Zynex, Inc. is a US stock , located in Englewood of Co and trading under the symbol ZYXI
Is Zynex, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $12.5. The lowest prediction is $7 and the highest is $18
What is ZYXI stock prediction ?
What is Zynex, Inc. stock quote today ?
Zynex, Inc. stock price is $8.265 today.
Is Zynex, Inc. stock public?
Yes, Zynex, Inc. is a publicly traded company.
Company Profile
- Volume Average 391.74K
- Market Capitalization 295.89M
- Employee 900
- CEO Mr. Thomas Sandgaard
- Headquarters Englewood,CO,US
- IPO Date 2004-02-25
-
Website
https://www.zynex.com 
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
